The global pharmaceutical industry experienced 0.67% rise in new job postings related to big data in Q3 2022 compared with the previous quarter, according to GlobalData’s Jobs Analytics. This is compared to the 0.67% increase in Q3 2021 and a 15% rise versus Q3 20201.
Notably, General and Operations Managers jobs accounted for an 8% share of the global pharmaceutical industry’s big data-related total new job postings in Q3 2022, up 0.37% over the prior quarter.
Major data-related job activity is driven by General and Operations Managers
General and Operations Managers topped the list of top big data roles in the pharmaceutical industry. New job postings rose by 0.3% quarter-on-quarter. With a share of 7 percent in Q3 2022 Software and Web Developers, Programmers, and Testers were second, with new job postings rising by 10% over the preceding quarter.
Other prominent roles in big data include Biological Scientists, who have a 6% share of Q3 2022’s job postings, and Database and Network Administrators and Architects who have a 3% share.
Top five pharmaceutical companies accounted for 2% in hiring activity
The top companies, in terms of number of new job postings tracked by GlobalData, as of Q3 2022 were Evolent Health , Johnson & Johnson, Intermountain Healthcare and Hastings Center. They combined accounted for 2% of all big-data-related active jobs within the pharmaceutical industry.
Evolent Health posted 2,137 jobs in Q3 2022 and registered a rise of 18% over the previous quarter, followed by Johnson & Johnson with 1,404 jobs and a 4% drop. Intermountain Healthcare, with 1,328 jobs, and Hastings Center, with 935 jobs, saw 0.3% growth and a 9.9% decrease, respectively. CVS Health, however, experienced a 4% drop with 804 job openings in Q3 2022.
US was the main driver of hiring activity, accounting for 78% percent of total job postings during Q3 2022
The US had 78% of the largest number of new jobs in big data in the pharmaceutical industry, followed by India (4%) or the UK (3%) in Q3 2022. The US represented 3% of the 75% that it represented in Q2 2022, compared to the 3% share.